Novavax, PATH sign RSV vaccine clinical development partnership
06:02 EDT 19 Jul 2012 | Pharmaceutical Business Review
Novavax and PATH have signed a clinical development partnership to develop the respiratory syncytial virus (RSV) vaccine.
Original Article: Novavax, PATH sign RSV vaccine clinical development partnership
More From BioPortfolio on "Novavax, PATH sign RSV vaccine clinical development partnership"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
